Mayuri Charnalia

Mayuri Charnalia

Auto-generated profile, based on publicly available information

Mayuri Charnalia

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SCSupriya Chopra
Supriya Chopra
NMNisarga Vontikoppal Manjunath
Nisarga Vontikoppal Manjunath
AGAnkita Gupta
Ankita Gupta
PMPrachi Mittal
Prachi Mittal
JJJeevanshu Jain
Jeevanshu Jain
SGSudeep Gupta
Sudeep Gupta

22 April 2024 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
MCMayuri Charnalia
Mayuri Charnalia
SCSupriya Chopra
Supriya Chopra
JMJaahid Mulani
Jaahid Mulani
PPPalak Popat
Palak Popat
SRSushmita Rath
Sushmita Rath
RNRemi Nout
Remi Nout
OBJECTIVE To investigate differences in standard clinico-radiological evaluation versus Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for reporting survival outcomes in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy. METHODS Between November 2017 and March 2020, patients recruited in cervical cancer trials were identified. MRI at diagnosis and at least one follow-up imaging was mandatory. Disease-free survival and progression-free survival were determined using standard evaluation (clinical examination and symptom-directed imaging) and RECIST 1.1. Agreement between criteria was estimated using κ value. Sensitivity analysis was done to test the sensitivity, specificity, and accuracy of RECIST 1.1 in detecting response to treatment. RESULTS Sixty-nine eligible patients had at least one target lesion. Thirty-three patients (47.8%) had pathological lymph nodes. Of these 33 patients, RECIST 1.1 classified only 18% (6/33) as ‘target nodal lesions’ and the remaining nodes as ‘non-target’. There were 6 (8.7%) and 8 (11.6%) patients with disease events using RECIST 1.1 and standard evaluation, respectively. The disease-free survival at 12, 18, and 24 months using RECIST 1.1 was 94.2%, 91.2%, 91.2%, and with standard evaluation was 94.2%, 89.7%, and 88.2%, respectively (p=0.58). Whereas, progression-free survival at 12, 18, and 24 months using RECIST 1.1 and standard evaluation were same (94.2%, 91.2%, and 91.2%, respectively). The κ value was 0.84, showing strong agreement in assessing disease-free survival, although an absolute difference of 3% between endpoint assessment methodologies. RECIST 1.1 had a sensitivity of 75% (95% CI 34.91% to 96.81%), specificity of 100% (95% CI 94.13% to 100%), and accuracy of 97.1% (95% CI 89.92% to 99.65%). CONCLUSIONS The study showed 1.5% and 3% difference in disease-free survival at 18 and 24 months and no difference in progression-free survival between RECIST 1.1 and standard evaluation in a patient cohort with low event rate.

14 February 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ACAnouk Corbeau
Anouk Corbeau
SSSofia Spampinato
Sofia Spampinato
MCMayuri Charnalia
Mayuri Charnalia
NRNilesh Ranjan
Nilesh Ranjan
SGSudeep Gupta
Sudeep Gupta
SCSupriya Chopra
Supriya Chopra
Gastrointestinal (GI) side effects are common after radiotherapy for gynecological cancers. Normal tissue complication probability (NTCP) models providing individual risk estimates for GI adverse events in gynecological cancers are not yet available. The aim of this study was to develop NTCP models for GI toxicity after postoperative (chemo)radiotherapy for cervical cancer. Data from the phase-III PARCER trial (NCT01279135) was used. Tested variables included patient- and treatment-related characteristics and dosimetric parameters of small, large, and total individual bowel loops, and bowel bag as peritoneal space. NTCP endpoints included acute and late ≥G2 diarrhea and GI toxicity (CTCAEv3.0) and late persistent GI toxicity defined with the Cumulative-Month and Severity Score (C-MOSES). Logistic or Cox regression were used for multivariable models, selecting variables with Least Absolute Shrinkage and Selection Operator. Internal model performance was evaluated with area-under-the-curve (AUC) or C-index. The median follow-up of the 283 included patients was 43 months. Volumes of the bowel receiving 30 Gy (V30Gy) and 40 Gy (V40Gy) were associated with acute and late ≥G2 diarrhea and persistent GI toxicity. IMRT reduced risk of late ≥G2 and persistent GI toxicity, whereas radical hysterectomy with bilateral lymphadenectomy increased it. AUC/C-indices ranged from 0.588 (persistent GI toxicity) to 0.761 (late ≥ G2 diarrhea). NTCP models for acute and late diarrhea and persistent GI toxicity after postoperative radiotherapy for cervical cancer included bowel V30Gy and V40Gy. Furthermore, 3DCRT and more extensive surgery increased risks. Further studies should explore additional variables to improve model performance, reach consensus on bowel delineation methods, and validate models externally.

20 March 2026 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MCMayuri Charnalia
Mayuri Charnalia
NRNilesh Ranjan
Nilesh Ranjan
SSSofia Spampinato
Sofia Spampinato
RNRemi Nout
Remi Nout
RPRichard Pötter
Richard Pötter
SCSupriya Chopra
Supriya Chopra